Exploring the tumor immunologic basis of the differential CRP kinetics after initiation of immunotherapy might further enhance our understanding of the interplay between the RCC tumor cells and its tumor microenvironment (TME).19, 20, 21. This evidence concerns the gene CRP and renal cell carcinoma.